Hims & Hers Redefines Virtual Care With Integrated Tech Platforms
HIMS accelerates global expansion with tech-integrated care, leveraging ZAVA and semaglutide for personalized health delivery.
Medifast's Q2 Earnings Beat Estimates, Lower Revenues Hurt Margins
MED's second-quarter 2025 earnings and sales decline as active earning OPTAVIA coaches dipped, hit by client acquisition.
Medifast ( MED ) Q2 Revenue Falls 37%
Medifast ( NYSE:MED ) , the nutrition and weight-loss company behind the OPTAVIA brand and its coach-based direct selling approach, reported its second quarter 2025 results on August 4, 2025. The company delivered revenue and earnings per share ahead of subdued Wall Street estimates, with GAAP ...
Clorox Q4 Earnings Beat Estimates, Organic Sales Increase Y/Y
CLX posts 57.7% EPS growth and 8% organic sales gain in the fourth quarter, fueled by strong ERP-driven volume increases.
Kraft Heinz Q2 Earnings Beat Estimates, Organic Sales Down 2% Y/Y
KHC tops Q2 estimates despite declines in earnings and organic sales, as pricing gains fail to offset weak volumes.
Health Meets Lifestyle: How Hims & Hers Is Reshaping Everyday Wellness
HIMS is transforming digital wellness with personalized care, over 30 million telehealth consultations, and a Gen Z-aligned platform.
Is Medifast Gaining or Losing Market Support? - Medifast ( NYSE:MED )
Medifast's MED short percent of float has fallen 5.04% since its last report. The company recently reported that it has 1.33 million shares sold short, which is 12.44% of all regular shares that are available for trading. Based on its trading volume, it would take traders 6.04 days to cover their ...
Mondelez ( MDLZ ) Down 2.2% Since Last Earnings Report: Can It Rebound?
Mondelez (MDLZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Mondelez's Innovation & Brand Strength Fueling Long-Term Growth
MDLZ's innovation, strong brand portfolio and global expansion position it for sustained growth, making the stock an appealing choice for long-term investors.
Medifast Q1 Loss Wider Than Expected, Sales Down 33.8% Y/Y
MED's first-quarter results show challenges from fewer active OPTAVIA Coaches. Nonetheless, the company is focusing on revitalizing its coach base for growth.
Medifast to Report Q1 Earnings: What Investors Should Expect
MED's first-quarter results may show challenges in customer acquisition amid market headwinds and shifting consumer trends.
Medifast Trades Near 52-Week Low: What's the Best Move Now?
MED faces steep revenue declines and coach losses but aims to rebound through innovation, marketing and new GLP-1-focused initiatives.
How Is The Market Feeling About Medifast? - Medifast ( NYSE:MED )
Medifast's MED short percent of float has risen 3.91% since its last report. The company recently reported that it has 1.39 million shares sold short, which is 19.38% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.6 days to cover their ...
MED Q4 Earnings Beat, Revenues Dip Y/Y on Lower Customer Acquisition
Medifast's Q2 results show challenges related to weak customer acquisition. However, it is prioritizing efforts to enhance coach productivity in the near term.
Medifast ( MED ) Q4 Earnings and Revenues Beat Estimates
Medifast (MED) delivered earnings and revenue surprises of 137.04% and 7.70%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
MED Focused on GLP-1 Solutions Amid Customer Acquisition Challenges
With a strategic focus on innovation and a robust operational framework, Medifast is well-placed for growth in the weight loss and GLP-1 medication space.
Medifast Launches OPTAVIA ASCEND for Weight Loss Management
MED's new OPTAVIA ASCEND product line combines high-protein meals, fiber-rich nutrients and personalized coaching.
Looking Into Medifast's Recent Short Interest - Medifast ( NYSE:MED )
Medifast's MED short percent of float has fallen 3.48% since its last report. The company recently reported that it has 1.60 million shares sold short, which is 22.18% of all regular shares that are available for trading. Based on its trading volume, it would take traders 6.81 days to cover their ...
Medifast ( MED ) Down 5.8% Since Last Earnings Report: Can It Rebound?
Medifast (MED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Do Options Traders Know Something About Medifast ( MED ) Stock We Don't?
Investors need to pay close attention to Medifast (MED) stock based on the movements in the options market lately.
Plant-based Beverage Market is Estimated to Reach $56.73 Billion with a 11.9% CAGR By 2034 | Fact.MR Reports
Rockville, MD, Nov. 20, 2024 ( GLOBE NEWSWIRE ) -- Fact.MR, a market research and competitive intelligence provider, through its new market analysis, mentioned that revenue from the plant-based beverage market is approximated to reach US$ 18.45 billion in 2024 and advance at a digit CAGR of ...
How Should You Play Medifast Stock at a P/E Multiple of 17.6X?
MED is battling customer acquisition challenges and high SG&A costs, while its strategic growth efforts keep it well-positioned for long-term success.
Are Investors Undervaluing MEDIFAST ( MED ) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
MED Q3 Earnings Beat, Revenues Fall on Customer Acquisition Challenges
Medifast's Q3 results lower earnings and revenues, highlighting challenges in customer acquisition. Management issues soft guidance for the fourth quarter.
Medifast ( MED ) Beats Q3 Earnings and Revenue Estimates
Medifast (MED) delivered earnings and revenue surprises of 333.33% and 3.48%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Medifast Gears Up for Q3 Earnings: Here's What You Should Know
MED's Q3 results may reflect customer acquisition challenges and a decline in active earning OPTAVIA Coaches due to the increasing adoption of GLP-1 medications.
Medifast Gears Up for Q3 Earnings: Here's What You Should Know
MED's Q3 results may reflect customer acquisition challenges and a decline in active earning OPTAVIA Coaches due to the increasing adoption of GLP-1 medications.
Medifast Drives Growth With Weight Loss Transformation Strategies
MED is striving to excel in the evolving weight loss market where GLP-1 medication adoption is reshaping the industry dynamics amid macroeconomic challenges.
Medifast Trades Near 52-Week Low: Buy, Hold or Sell MED Stock?
Amid hurdles like competition and a dynamic consumer landscape, Medifast is taking steps to realign its strategy and capitalize on emerging opportunities.
Medifast ( MED ) Down 11.5% Since Last Earnings Report: Can It Rebound?
Medifast (MED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Medifast's ( MED ) Strategies Aid Amid Evolving Market Demands
Medifast (MED) is making efforts to thrive in the rapidly evolving weight loss market, as the adoption of GLP-1 medications reshapes industry dynamics.
Medifast ( MED ) Tumbles 25% in 3 Months: Should You Buy Now?
Medifast (MED) is encountering difficulties in attracting customers due to a reduction in the number of active OPTAVIA Coaches and diminished productivity per Coach.
Medifast ( MED ) Q2 Earnings Beat Estimates, Revenues Fall Y/Y
Medifast's (MED) Q2 results highlight the challenges of poor customer acquisition. However, the company is focusing strategically on medically supported weight loss, indicating potential for growth.
Medifast ( MED ) Q2 Earnings and Revenues Beat Estimates
Medifast (MED) delivered earnings and revenue surprises of 155.56% and 5.06%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Medifast ( MED ) Q2 Earnings in the Cards: Factors to Watch
Medifast's (MED) Q2 results are likely to reflect customer acquisition challenges stemming from the growth of GLP-1 medications in markets.
Post Holdings ( POST ) Q3 Earnings Surpass Estimates
Post Holdings (POST) delivered earnings and revenue surprises of 27.27% and 3.22%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Medifast ( MED ) Lags Industry in 3 Months: How to Play Ahead?
While Medifast (MED) is implementing a series of measures to propel its growth trajectory, the challenges related to customer acquisition and high marketing expenses keep it in a tight spot.
ETFs in Focus on the Upcoming S&P 500 Shake-Up
KKR (KKR), CrowdStrike (CRWD) and GoDaddy (GDDY) will enter the S&P 500, replacing Robert Half (RHI), Comerica (CMA) and Illumina (ILMN).
Medifast ( MED ) Tumbles More Than 40% in 3 Months: Here's Why
Medifast (MED) battles persistent customer acquisition challenges aggravated by macroeconomic factors and the rising popularity of weight loss medications.
Looking Into Medifast's Recent Short Interest - Medifast ( NYSE:MED )
Medifast's MED short percent of float has risen 3.9% since its last report. The company recently reported that it has 3.24 million shares sold short, which is 45.02% of all regular shares that are available for trading. Based on its trading volume, it would take traders 6.34 days to cover their ...
( MED ) - Analyzing Medifast's Short Interest - Medifast ( NYSE:MED )
Medifast's MED short percent of float has risen 11.91% since its last report. The company recently reported that it has 2.99 million shares sold short, which is 41.53% of all regular shares that are available for trading. Based on its trading volume, it would take traders 8.53 days to cover their ...
Top 4 Defensive Stocks You'll Regret Missing This Quarter - Medifast ( NYSE:MED ) , Australian Oilseeds Hldgs ( NASDAQ:COOT )
The most oversold stocks in the consumer staples sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down.
Gold Down Over 2%; 3M Profit Beats Expectations - 3M ( NYSE:MMM )
U.S. stocks traded lower toward the end of trading, with the Dow Jones falling around 1% on Tuesday. The Dow traded down 0.99% to 38,005.55 while the NASDAQ fell 1.09% to 15,808.29. The S&P 500 also fell, dropping, 0.85% to 5,072.88. Health care shares rose by 0.1% on Tuesday.
Nasdaq Dips Over 100 Points; Coca-Cola Earnings Top Views - Coca-Cola ( NYSE:KO )
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 100 points on Tuesday. The Dow traded down 0.81% to 38,073.65 while the NASDAQ fell 0.80% to 15,855.75. The S&P 500 also fell, dropping, 0.70% to 5,080.52. Health care shares rose by 0.1% on Tuesday.
Medifast ( MED ) Q1 Earnings Miss Estimates, Revenues Fall Y/Y
Medifast's (MED) first-quarter results reflect challenges related to a decline in active earning OPTAVIA Coaches, lower coach productivity and soft sales volume.
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Medifast, Inc. and Encourages Investors to Contact the Firm - Medifast ( NYSE:MED )
LOS ANGELES, April 30, 2024 ( GLOBE NEWSWIRE ) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medifast, Inc. ( "Medifast" or "the Company" ) MED for violations of the securities laws.
Dow Tumbles 200 Points; McDonald's Posts Downbeat Earnings - McDonald's ( NYSE:MCD )
U.S. stocks traded lower this morning, with the Dow Jones index falling more than 200 points on Tuesday. Following the market opening Tuesday, the Dow traded down 0.59% to 38,159.97 while the NASDAQ fell 0.23% to 15,945.74. The S&P 500 also fell, dropping, 0.23% to 5,104.26.
Why GeneDx Shares Are Trading Higher By 37%; Here Are 20 Stocks Moving Premarket - GeneDx Hldgs ( NASDAQ:WGS )
Shares of GeneDx Holdings Corp. WGS rose sharply in today's pre-market trading after the company reported better-than-expected first-quarter financial results and raised its FY2024 sales guidance. GeneDx reported quarterly losses of 33 cents per share which beat the analyst consensus estimate of ...
Medifast Reports Mixed Results, Joins Coursera, Chegg And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Chegg ( NYSE:CHGG ) , Medifast ( NYSE:MED )
U.S. stock futures were slightly lower this morning, with the Nasdaq futures falling around 0.1% on Tuesday. Shares of Medifast, Inc. MED fell sharply in today's pre-market trading after the company reported mixed first-quarter financial results.
How Is The Market Feeling About Medifast? - Medifast ( NYSE:MED )
Medifast's MED short percent of float has risen 29.89% since its last report. The company recently reported that it has 2.66 million shares sold short, which is 37.11% of all regular shares that are available for trading. Based on its trading volume, it would take traders 6.6 days to cover their ...
